Abstract: Certain alkenyl diamines, the use of same for disinfecting and cleaning contact lenses and preserving ophthalmic products, and associated ophthalmic compositions are described.
Type:
Grant
Filed:
October 25, 1993
Date of Patent:
May 16, 1995
Assignee:
Alcon Laboratories, Inc.
Inventors:
Rolf Schafer, Ronald L. Schlitzer, Nissanke L. Dassanayake
Abstract: The use of TGF-.beta..sub.3 to reduce the formation of scar tissue as a result of trauma to the cornea of the eye is described. The invention is particularly directed to the use of TGF-.beta..sub.3 to reduce the formation of scar tissue in connection with ophthalmic surgical procedures involving the cornea, such as laser irradiation of the cornea. A composition containing TGF-.beta..sub.3 is applied to the site of the trauma to alter the production and composition of extracellular matrix synthesized by fibroblasts, and thereby reduce the formation of scar tissue and consequent impairment of vision.
Abstract: Disclosed are solutions useful in surgery comprising a viscous or viscoelastic substance in an aqueous vehicle which is characterized as physiologically compatible; also disclosed are methods of using such solutions, implanting such viscous or viscoelastic substances, while minimizing the traumatic effect of surgery at the cellular level.
Abstract: Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and an angiostatic steroid. The angiostatic steroid substantially prevents any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent anti-inflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure.
Abstract: Topical ophthalmic compositions of carrageenans which are administrable as a drop but which become more viscous or gel upon instillation in the eye are disclosed. Methods for use of the compositions as topical ophthalmic vehicles for pharmaceutically active agents, and alone as lubricants or tear supplements, are also disclosed.
Type:
Grant
Filed:
August 18, 1993
Date of Patent:
April 4, 1995
Assignee:
Alcon Laboratories, Inc.
Inventors:
John C. Lang, Jamieson C. Keister, Paul J. T. Missel, Dimitri J. Stancioff
Abstract: Non-preserved physiological tear compositions comprise the ionic components of normal human tear film in substantially the same amounts and proportions. Novel methods of preparation of these compositions and novel packaging allow the maintenance of the bicarbonate concentration in these compositions.
Type:
Grant
Filed:
January 6, 1994
Date of Patent:
April 4, 1995
Assignee:
Alcon Laboratories, Inc.
Inventors:
Robert E. Beck, Haresh G. Bhagat, Philip D. Gressel, Fred M. Killinger
Abstract: Methods for preventing and treating corneal haze resulting from exposure of the eye to laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators to the eye. Compositions for use in preventing and treating the corneal haze are also disclosed.
Type:
Grant
Filed:
July 25, 1994
Date of Patent:
March 28, 1995
Assignee:
Alcon Laboratories, Inc.
Inventors:
Stella M. Robertson, Herman M. Kunkle, Jr.
Abstract: Methods for preventing and treating corneal haze resulting from exposure of the eye to laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators to the eye. Compositions for use in preventing and treating the corneal haze are also disclosed.
Type:
Grant
Filed:
July 25, 1994
Date of Patent:
March 28, 1995
Assignee:
Alcon Laboratories, Inc.
Inventors:
Stella M. Robertson, Herman M. Kunkle, Jr.
Abstract: Certain amidoamines, the use of same for disinfecting and cleaning contact lenses and preserving ophthalmic products, and associated ophthalmic compositions are described.
Type:
Grant
Filed:
September 22, 1993
Date of Patent:
February 28, 1995
Assignee:
Alcon Laboratories, Inc.
Inventors:
Nissanke L. Dassanayake, Ronald L. Schlitzer, Joonsup Park
Abstract: Sulfonamides and pharmaceutical compositions containing the compounds useful in controlling intraocular pressure are disclosed. Methods for controlling intraocular pressure through administration of the compositions are also disclosed.
Type:
Grant
Filed:
February 18, 1993
Date of Patent:
January 3, 1995
Assignee:
Alcon Laboratories, Inc.
Inventors:
Thomas R. Dean, Hwang-Hsing Chen, Jesse A. May
Abstract: Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatic steroids and methods for their use in treating ocular hypertension, including controlling the ocular hypertension associated with primary open angle glaucoma, are disclosed. In addition, the combination of the compounds with glucocorticoids for the prevention of elevated IOP during the treatment of inflammation is disclosed.
Abstract: An improved process for cleaning and disinfecting contact lenses with a single solution is described. The process utilizes the cleaning effect of a cleaning agent in combination with the solvent action of water and physical agitation of the lens (i.e., by means of rubbing) to achieve a degree of cleaning which is comparable to or better than prior processes which utilize surfactant-cleaners. The cleaning agent is selected from polycarboxylates, polysulfonates and polyphosphates. The preferred cleaning agent is citrate. The process also offers greater convenience, relative to many prior systems for cleaning and disinfecting contact lenses, since the need to utilize additional products to clean the lenses is eliminated.
Type:
Grant
Filed:
August 27, 1993
Date of Patent:
December 6, 1994
Assignee:
Alcon Laboratories, Inc.
Inventors:
Masood Chowhan, Thierry Bilbault, Ronald P. Quintana
Abstract: The use of substituted glycosides to enhance the penetration of drugs across mucus covered epithelial tissues of humans and animals is disclosed, including enhanced penetrations of topically applied ophthalmic drugs through the corneal epithelium of said humans and animals.
Abstract: Disclosed is a process for heat sterilizing pharmaceuticals, cosmetics, foodstuffs and other materials, which are labile to oxidation by atmospheric oxygen at elevated temperature and labile to other degradative changes through interaction with volatiles raised by exposure of the material to elevated temperature, comprising heating, for a given length of time, the material to be sterilized at a temperature required to achieve a predetermined degree of sterilization in a gaseous medium substantially devoid of oxygen; typically such a gaseous medium comprises a non reactive gas, such as, nitrogen, which is otherwise innocuous and capable of being purged at the end of the sterilization process at a pressure sufficient to facilitate the distribution of heat throughout the material being treated by convection.
Abstract: Methods for treating the cornea following UV laser irradiation and resulting photoablation of corneal tissue are disclosed. The methods include administration of compositions of a non-steroidal antiinflammatory to the eye. Compositions for use in treating the cornea are also disclosed.
Type:
Grant
Filed:
August 4, 1993
Date of Patent:
November 1, 1994
Assignee:
Alcon Laboratories, Inc.
Inventors:
Stella M. Robertson, Herman M. Kunkle, Jr.
Abstract: By allowing the mast cell enriched population of human conjunctival tissue cells to incubate for a minimum of about forty (40) hours post enzymatic digestion, the treatment window between spontaneous histamine release and anti-human IgE stimulated histamine release is increased. Culturing the human conjunctival tissue mast cells decreases the spontaneous release of histamine and increases the anti-IgE stimulated histamine release, greater than ten fold over spontaneous, at time points over forty (40) hours. This treatment window is sufficient to detect a compound's stabilizing or anti-allergic activity.
Abstract: Compositions and methods for controlling intraocular pressure using transition metal complexes are disclosed. Topical ophthalmic and systemic administration of the transition metal complexes is disclosed.
Type:
Grant
Filed:
August 9, 1993
Date of Patent:
October 18, 1994
Assignee:
Alcon Laboratories, Inc.
Inventors:
Hans R. Moll, Mark T. DuPriest, Daniel Kuzmich